Insulin + Glucose Pediatric Dose — Hyperkalemia

Regular insulin combined with glucose is a cornerstone pharmacologic intervention for acute hyperkalemia in pediatric patients. Insulin drives potassium intracellularly via activation of the Na⁺/K⁺-ATPase pump, and co-administration of glucose prevents iatrogenic hypoglycemia. This combination is used across inpatient and critical care settings whenever rapid, temporary reduction of serum potassium is required.

Pediatric Dosing

For acute hyperkalemia, administer 0.1 unit/kg Regular insulin with 0.5 g/kg glucose as a co-infusion over 30–60 minutes.

• Regular Insulin: 0.1 unit/kg IV
• Glucose: 0.5 g/kg IV (co-administered)
• Infusion duration: 30–60 minutes

Worked example — 20 kg child: 20 × 0.1 unit/kg = 2 units Regular insulin; 20 × 0.5 g/kg = 10 g glucose (e.g., 100 mL of D10W), infused together over 30–60 minutes. Consult institutional protocol for specific dextrose concentration and maximum doses.

Indications and Clinical Context

This regimen is indicated for the acute management of hyperkalemia in pediatric patients, including etiologies such as renal failure, tumor lysis syndrome, rhabdomyolysis, acidosis, and drug-related toxicity. It is classified as a transcellular shift intervention — it does not eliminate potassium from the body but transiently reduces serum levels, typically within 15–30 minutes of infusion, buying time while definitive therapies (e.g., kayexalate, dialysis) are arranged.

In toxicologic and critical care contexts, this combination is frequently used alongside other interventions such as calcium (for membrane stabilization) and sodium bicarbonate. Continuous cardiac monitoring is warranted given the dysrhythmia risk associated with significant hyperkalemia.

Administration and Monitoring

Administer via a reliable IV access; central venous access is preferred for concentrated dextrose solutions to reduce the risk of extravasation injury, though peripheral access may be used with appropriately diluted preparations. The insulin and glucose should be co-infused concurrently over 30–60 minutes as specified.

• Route: IV (preferred); IO may be used in emergencies per institutional protocol
• Key monitoring: Blood glucose every 15–30 minutes during and for at least 1–2 hours after the infusion to detect hypoglycemia
• Serum potassium: Recheck 1–2 hours post-infusion to assess response
• Cardiac monitoring: Continuous ECG during the infusion
• Adverse effects: Hypoglycemia (most common), hypokalemia with repeated dosing

Consult institutional protocol for guidance on maximum doses and dextrose concentration selection based on patient age and access type.

---

Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.